Twist Bioscience (NASDAQ:TWST) Stock: Insider Adam Laponis Sells 2,462 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,462 shares of the company’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the sale, the chief financial officer owned 98,114 shares in the company, valued at $15,335,218.20. This represents a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16.

Twist Bioscience Trading Down 0.3%

TWST traded down $0.53 on Tuesday, hitting $151.33. The company had a trading volume of 1,528,138 shares, compared to its average volume of 1,708,576. The business’s fifty day simple moving average is $145.34 and its 200 day simple moving average is $97.50. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The company has a market cap of $9.49 billion, a PE ratio of -68.17 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the company earned $0.33 earnings per share. Equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TWST. Piper Sandler boosted their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Barclays lifted their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Leerink Partners lifted their price objective on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, TD Cowen boosted their price objective on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $143.67.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the business. Allworth Financial LP purchased a new stake in shares of Twist Bioscience in the second quarter valued at approximately $62,000. Trifecta Capital Advisors LLC purchased a new position in Twist Bioscience during the 2nd quarter worth $63,000. Western Wealth Management LLC purchased a new position in Twist Bioscience during the 1st quarter worth $31,000. Strs Ohio bought a new stake in Twist Bioscience during the 1st quarter valued at $33,000. Finally, GAMMA Investing LLC raised its position in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.